Akebia Therapeutics
AKBA
Market cap $935M

3.56 USD

-0.09

2.47%

At close Jun 13, 4:00 PM EDT

After hours

3.55

-0.01

0.28%

1 day

-2.47%

5 days

-11.88%

1 month

43.55%

3 months

110.65%

6 months

92.43%

Year to date

87.37%

1 year

217.86%

5 years

-70.65%

10 years

-55.94%

About: Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Employees: 181

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

675% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 4

156% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 25

58% more capital invested

Capital invested by funds: $129M [Q4 2024] → $203M (+$74.3M) [Q1 2025]

19% more funds holding

Funds holding: 121 [Q4 2024] → 144 (+23) [Q1 2025]

5.46% more ownership

Funds ownership: 31.1% [Q4 2024] → 36.56% (+5.46%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

45% less call options, than puts

Call options by funds: $654K | Put options by funds: $1.19M

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

69%

upside

Avg. target

$7.13

100%

upside

High target

$8

125%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Matthew Caufield	125%upside $8	Buy Assumed	4 Jun 2025
Leerink Partners Roanna Ruiz	97%upside $7	Outperform Initiated	28 Apr 2025
HC Wainwright & Co. Ed Arce	111%upside $7.50	Buy Reiterated	4 Apr 2025
Jefferies Roger Song	69%upside $6	Buy Initiated	1 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about AKBA published over the past 30 days

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® (vadadustat) Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® (vadadustat)

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 137,000 shares of Akebia's common stock on May 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 8:45 AM EDT.

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

Vadadustat clinical data on display for nephrologists and healthcare providers Vadadustat clinical data on display for nephrologists and healthcare providers

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, and Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C.

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Chief Business Officer Conference Call Participants Roanna Ruiz - Leerink Partners Roger Song - Jefferies Allison Bratzel - Piper Sandler Les Siloski - Truist Securities Operator Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call.

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates

Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of $113.4 million as of the end of the quarter Akebia to Host Conference Call at 8:00 a.m. ET on May 8, 2025 CAMBRIDGE, Mass.

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia's common stock on April 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

See News Rankings

Charts implemented using Lightweight Charts™